Montoney M, Gardell S J, Marder V J
Department of Medicine, University of Rochester (NY) School of Medicine and Dentistry 14642.
Circulation. 1995 Mar 1;91(5):1540-4. doi: 10.1161/01.cir.91.5.1540.
Vampire bat salivary plasminogen activator (Bat-PA) has significantly greater fibrin specificity than any of the fibrinolytic agents currently in clinical use. This study tests the hypothesis that avoiding fibrinogen depletion may protect against the hemorrhage induced by plasminogen activator treatment.
Bat-PA was compared with tissue-type plasminogen activator (TPA) in a randomized, prospective, and blinded study using a rabbit ear puncture model of fibrinolytic bleeding. The two agents were used at equimolar dosages (42 nmol/kg) that yielded similar thrombolytic efficacies in a rabbit femoral artery thrombosis model. Both Bat-PA and TPA prolong primary bleeding to double the baseline values, from between 2.1 and 2.3 minutes to between 4.8 and 5.2 minutes. Rebleeding from hemostatically stable sites during the 3-hour observation period occurred equally often with Bat-PA and TPA, 31% from preinjection sites and 23% to 25% from postinjection sites. The lag time between the time of plasminogen activator injection and the onset of rebleeding was likewise the same for both agents, most occurring at 41 to 57 minutes. However, a greater number of prolonged primary or rebleeding occurrences continued for longer than 10 minutes (63% versus 36%) or longer than 30 minutes (30% versus 10%) after Bat-PA than TPA injection. Animals treated with TPA showed a dramatic decrease in plasma fibrinogen and factor VIII concentrations, but those in the Bat-PA treatment group showed only a slight decrease from control values.
The results indicate that fibrinolytic bleeding after plasminogen activator infusion into rabbits did not correlate with the intensity of the plasma proteolytic state. If anything, Bat-PA usage was associated with a higher proportion of more protracted fibrinolytic bleeding episodes, despite the relatively mild lytic state in comparison with that induced by TPA.
吸血蝙蝠唾液纤溶酶原激活剂(Bat-PA)比目前临床使用的任何纤溶药物具有更高的纤维蛋白特异性。本研究检验了如下假设:避免纤维蛋白原消耗可预防纤溶酶原激活剂治疗引起的出血。
在一项随机、前瞻性、双盲研究中,使用纤维蛋白溶解出血的兔耳穿刺模型,将Bat-PA与组织型纤溶酶原激活剂(TPA)进行比较。两种药物以等摩尔剂量(42 nmol/kg)使用,在兔股动脉血栓形成模型中产生相似的溶栓效果。Bat-PA和TPA均使初始出血时间延长至基线值的两倍,从2.1至2.3分钟延长至4.8至5.2分钟。在3小时观察期内,止血稳定部位的再出血在Bat-PA和TPA组中发生频率相同,注射前部位为31%,注射后部位为23%至25%。纤溶酶原激活剂注射时间与再出血开始之间的延迟时间在两种药物中同样相同,大多数发生在41至57分钟。然而,与TPA注射后相比,Bat-PA注射后更多的初始或再出血延长事件持续超过10分钟(63%对36%)或超过30分钟(30%对10%)。接受TPA治疗的动物血浆纤维蛋白原和因子VIII浓度显著降低,但Bat-PA治疗组动物仅比对照值略有降低。
结果表明,向兔体内注入纤溶酶原激活剂后的纤维蛋白溶解出血与血浆蛋白水解状态的强度无关。相比之下,尽管Bat-PA诱导的溶解状态相对较轻,但使用Bat-PA与更长时间的纤维蛋白溶解出血发作比例较高有关。